Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 13/20 | 0.51 |
| ▸ | EGFR | P00533 | 4/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.51 |
| ▸ | PI4KA | P42356 | 2/20 | 0.48 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.48 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.48 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.48 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22417147 | 0.86 | MAP4K4 (0.49) | MAP4K4PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL10967457 | 0.79 | LIMK1 (0.52) | MAP4K4 | |
| SCHEMBL17665860 | 0.78 | MAP4K4 (0.61) | MAP4K4 | |
| SCHEMBL10969193 | 0.76 | MAP4K4 (0.76) | MAP4K4EGFR | |
| SCHEMBL14536930 | 0.76 | MAP4K4 (0.76) | MAP4K4EGFR | |
| SCHEMBL10970822 | 0.76 | MAP4K4 (0.58) | MAP4K4EGFR | |
| SCHEMBL685458 | 0.76 | MAP4K4 (0.68) | MAP4K4PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL31216400 | 0.76 | MAP4K4 (0.68) | MAP4K4PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL179504 | 0.75 | MAP4K4 (0.51) | MAP4K4PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL4692556 | 0.75 | MAP4K4 (0.66) | MAP4K4EGFRPI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070752-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | VIRACTA THERAPEUTICS, INC. | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070752-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | MAP4K4 147/4885EGFR 2844/4885ERBB2 1845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.